Umibecestat
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Aug 10, 2015 (NCT02576639)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta-secretase 1INHIBITOR
BACE1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cnp520
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03131453 | Phase 2/Phase 3 (Phase 3) | Jun 22, 2017 | Amgen, Novartis, University of Arizona |
| NCT02565511 | Phase 2/Phase 3 (Phase 3) | Dec 2, 2015 | Alzheimer's Association, Amgen, National Institute on Aging (NIA), Novartis, University of Arizona |
| NCT02576639 | Phase 2 | Aug 10, 2015 | Novartis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 3 | 3 | 2 | 2015 |
| Amgen | For profit | 2 | 0 | 1 | 2015 |
| University of Arizona | Academic/Hospital | 2 | 0 | 1 | 2015 |
| Alzheimer's Association | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1